0001209191-22-025515.txt : 20220425
0001209191-22-025515.hdr.sgml : 20220425
20220425161106
ACCESSION NUMBER: 0001209191-22-025515
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220421
FILED AS OF DATE: 20220425
DATE AS OF CHANGE: 20220425
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wolchko J Scott
CENTRAL INDEX KEY: 0001586893
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36076
FILM NUMBER: 22849795
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FATE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001434316
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 651311552
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
BUSINESS PHONE: 858.875.1803
MAIL ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-21
0
0001434316
FATE THERAPEUTICS INC
FATE
0001586893
Wolchko J Scott
C/O FATE THERAPEUTICS, INC.
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO
CA
92131
1
1
0
0
President and CEO
Common Stock
2022-04-21
4
M
0
30000
2.70
A
461546
D
Common Stock
2022-04-21
4
S
0
22715
34.57
D
438831
D
Common Stock
2022-04-21
4
S
0
4062
35.73
D
434769
D
Common Stock
2022-04-21
4
S
0
2220
36.70
D
432549
D
Common Stock
2022-04-21
4
S
0
1003
37.90
D
431546
D
Common Stock
2022-04-22
4
M
0
10000
2.70
A
441546
D
Common Stock
2022-04-22
4
S
0
9162
34.54
D
432384
D
Common Stock
2022-04-22
4
S
0
838
35.15
D
431546
D
Stock Option (Right to Buy)
2.70
2022-04-21
4
M
0
30000
2.70
D
2027-01-03
Common Stock
30000
46246
D
Stock Option (Right to Buy)
2.70
2022-04-22
4
M
0
10000
2.70
D
2027-01-03
Common Stock
10000
36246
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.
Represents the weighted average sale price of the shares sold from $34.22 to $35.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7.
Represents the weighted average sale price of the shares sold from $35.29 to $36.25 per share.
Represents the weighted average sale price of the shares sold from $36.29 to $37.08 per share.
Represents the weighted average sale price of the shares sold from $37.70 to $38.38 per share.
Represents the weighted average sale price of the shares sold from $34.04 to $35.03 per share.
Represents the weighted average sale price of the shares sold from $35.04 to $35.29 per share.
This option is fully vested.
/s/ Cindy Tahl, as Attorney-in-Fact
2022-04-25